Form 8-K - Current report:
SEC Accession No. 0001193125-26-009642
Filing Date
2026-01-12
Accepted
2026-01-12 06:02:55
Documents
12
Period of Report
2026-01-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mbx-20260111.htm   iXBRL 8-K 53866
2 EX-99.1 mbx-ex99_1.htm EX-99.1 38064
3 GRAPHIC img258572290_0.jpg GRAPHIC 34644
  Complete submission text file 0001193125-26-009642.txt   263000

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mbx-20260111.xsd EX-101.SCH 26956
14 EXTRACTED XBRL INSTANCE DOCUMENT mbx-20260111_htm.xml XML 5116
Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42272 | Film No.: 26524524
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)